resTORbio, Inc.

The founding of Altos Labs in January 2022, which launched with a record $3bn in venture capital funding from high-profile backers that reportedly include Amazon founder Jeff Bezos and billionaire e

Public biopharmaceutical company valuations have taken a sharp turn into the red in the US during the past month, plunging the industry’s market for initial public offering into a drought. This trend

Scrip regularly covers business development and deal-making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker . Menarini To Pay $11.50 Per Share In

After ResTORbio Inc. ’s RTB101 failed to meet the primary endpoint in the first of two Phase III studies, the company immediately cancelled the second study, abandoning the lead indication of clinica